Literature DB >> 28278718

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.

Jonathon B Cohen1, Kami J Maddocks2, Ying Huang2, Beth A Christian2, Samantha M Jaglowski2, Christopher R Flowers1, Kristie A Blum2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28278718      PMCID： PMC5497734          DOI： 10.1080/10428194.2017.1289527

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

2.  Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Arijit Chakravarty; Lee Silverman; Mengkun Zhang; Kara M Hoar; Stephen G Stroud; Wei Chen; Vaishali Shinde; Jessica J Huck; Deborah R Wysong; David A Janowick; Marc L Hyer; Patrick J Leroy; Rachel E Gershman; Matthew D Silva; Melissa S Germanos; Joseph B Bolen; Christopher F Claiborne; Todd B Sells
Journal:  Clin Cancer Res       Date:  2011-10-20       Impact factor: 12.531

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.

Authors:  Wenqing Qi; Laurence S Cooke; Xiaobing Liu; Lisa Rimsza; Denise J Roe; Ann Manziolli; Daniel O Persky; Thomas P Miller; Daruka Mahadevan
Journal:  Biochem Pharmacol       Date:  2011-02-01       Impact factor: 5.858

5.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Kevin R Kelly; Thomas C Shea; André Goy; Jesus G Berdeja; Craig B Reeder; Kevin T McDonagh; Xiaofei Zhou; Hadi Danaee; Hua Liu; Jeffrey A Ecsedy; Huifeng Niu; Ely Benaim; Swaminathan Padmanabhan Iyer
Journal:  Invest New Drugs       Date:  2013-12-20       Impact factor: 3.850
  6 in total
  1 in total

1.  A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.

Authors:  Paolo Strati; Loretta J Nastoupil; Richard E Davis; Luis E Fayad; Nathan Fowler; Fredrick B Hagemeister; Larry Kwak; Yasuhiro Oki; Michael Wang; Jason Westin; Charnelle E Ruben; Emily T Wesson; Richard Piekarz; Michelle A Fanale; Hun Ju Lee
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.